{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:13:55Z","timestamp":1778174035978,"version":"3.51.4"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104905","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:52:27Z","timestamp":1755553947000},"page":"104905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Research progress and future perspectives of prodrug strategies for immune checkpoint inhibitors in cancer immunotherapy"],"prefix":"10.1016","volume":"214","author":[{"given":"Tingyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.104905_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104905_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106264","article-title":"Overcoming immunotherapeutic resistance in PDAC: SIRP\u03b1-CD47 blockade","volume":"181","author":"Alausa","year":"2022","journal-title":"Pharm. Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104905_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/2326-6066.CIR-21-0031","article-title":"Conditional PD-1\/PD-L1 probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional Anti-PD-1\/PD-L1 agents","volume":"9","author":"Assi","year":"2021","journal-title":"Cancer Immunol. Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104905_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104905_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cytogfr.2017.06.002","article-title":"Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer","volume":"36","author":"Bellone","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2025.104905_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104905_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004904","article-title":"Real-world clinical outcomes with avelumab in patients with merkel cell carcinoma treated in the USA: a multicenter chart review study","volume":"10","author":"Bhatia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104905_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104905_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med"},{"issue":"S11","key":"10.1016\/j.critrevonc.2025.104905_bib12","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cncr.30444","article-title":"Immune and molecular correlates in melanoma treated with immune checkpoint blockade","volume":"123","author":"Byrne","year":"2017","journal-title":"Cancer"},{"issue":"10304","key":"10.1016\/j.critrevonc.2025.104905_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104905_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104905_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for Immune-Related adverse events: a practical guide to identifying High-Risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol. Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104905_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of IDO1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"38","key":"10.1016\/j.critrevonc.2025.104905_bib18","article-title":"Light-Triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy","volume":"36","author":"Choi","year":"2024","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib19","doi-asserted-by":"crossref","first-page":"12086","DOI":"10.1021\/acsnano.1c03416","article-title":"Visible-Light-Triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"15","author":"Choi","year":"2021","journal-title":"ACS Nano"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104905_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in Renal-Cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104905_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharm. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104905_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902960","article-title":"Self-Amplified drug delivery with Light-Inducible nanocargoes to enhance cancer immunotherapy","volume":"31","author":"Feng","year":"2019","journal-title":"Adv. Mater."},{"issue":"38","key":"10.1016\/j.critrevonc.2025.104905_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201803001","article-title":"Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment","volume":"30","author":"Feng","year":"2018","journal-title":"Adv. Mater."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104905_bib25","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-19-3137","article-title":"Probody therapeutic design of (89)Zr-CX-072 promotes accumulation in PD-L1-Expressing tumors compared to normal murine lymphoid tissue","volume":"26","author":"Giesen","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104905_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4578","article-title":"Design of a protease-activated PD-L1 inhibitor","volume":"32","author":"Goudy","year":"2023","journal-title":"Protein Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102050","article-title":"Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice","volume":"8","author":"Grivas","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104905_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121018","article-title":"Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy","volume":"276","author":"Guo","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2025.104905_bib29","doi-asserted-by":"crossref","DOI":"10.2174\/0115701638324854250218053353","article-title":"Targeted management: unlocking the crucial role of PROTACs in cancer treatment","author":"Gupta","year":"2025","journal-title":"Curr. Drug Discov. Technol."},{"issue":"530","key":"10.1016\/j.critrevonc.2025.104905_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0876","article-title":"Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies","volume":"12","author":"Gurbatri","year":"2020","journal-title":"Sci. Transl. Med"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104905_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26154640","article-title":"IEDDA: an attractive bioorthogonal reaction for biomedical applications","volume":"26","author":"Handula","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib32","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1021\/jacs.9b12232","article-title":"Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2,3-Dioxygenase","volume":"142","author":"Han","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.critrevonc.2025.104905_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab versus chemotherapy in patients with Platinum-treated locally advanced or metastatic urothelial carcinoma: a Long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial","volume":"80","author":"van der Heijden","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/anie.201905171","article-title":"New designs for phototherapeutic transition metal complexes","volume":"59","author":"Imberti","year":"2020","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/2159-8290.CD-NB2017-056","article-title":"Triggers responses in melanoma","volume":"7","author":"Indoximod Combo","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib37","first-page":"747","article-title":"Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC","volume":"51","author":"Ippolito","year":"2024","journal-title":"J. Pharm. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104905_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/jjco\/hyz208","article-title":"Corrigendum to: subgroup analysis of Japanese patients in a phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)","volume":"50","author":"Iwata","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"10294","key":"10.1016\/j.critrevonc.2025.104905_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-023-00508-5","article-title":"Rare Immune-Related adverse events (irAEs): approach to diagnosis and management","volume":"38","author":"Javaid","year":"2024","journal-title":"Pharm. Med"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104905_bib41","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib42","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as First-Line therapy for metastatic Non-Small-Cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib43","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib45","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","article-title":"A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib46","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011636","article-title":"Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC","volume":"13","author":"Kim","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104905_bib49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104905_bib50","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104905_bib51","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.104905_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.104905_bib53","doi-asserted-by":"crossref","first-page":"32933","DOI":"10.1021\/jacs.4c06160","article-title":"Conditionally activatable chimeras for tumor-specific membrane protein degradation","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.critrevonc.2025.104905_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119933","article-title":"Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy","volume":"242","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2025.104905_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112838","article-title":"Novel pH-sensitive nanoparticles based on prodrug strategy to delivery All-Trans retinoic acid for breast cancer","volume":"219","author":"Li","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.critrevonc.2025.104905_bib56","article-title":"Target tumor microenvironment by innate t cells","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib57","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1016\/j.apsb.2024.02.024","article-title":"Sequential dual-locking strategy using photoactivated Pt(IV)-based metallo-nano prodrug for enhanced chemotherapy and photodynamic efficacy by triggering ferroptosis and macrophage polarization","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111756","article-title":"Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer","volume":"11","author":"Marhelava","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104905_bib62","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fimmu.2019.00846","article-title":"Immune checkpoint molecules in reproductive immunology","volume":"10","author":"Miko","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib63","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.7150\/thno.69119","article-title":"Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death","volume":"12","author":"Moon","year":"2022","journal-title":"Theranostics"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104905_bib64","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104905_bib65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib66","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104905_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors","volume":"4","author":"Muhaj","year":"2023","journal-title":"Front Allergy"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002447","article-title":"CX-072 (pacmilimab), a probody (\u00ae) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study","volume":"9","author":"Naing","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib69","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1021\/acsnano.3c11186","article-title":"Immunomodulatory prodrug micelles imitate mild heat effects to reshape tumor microenvironment for enhanced cancer immunotherapy","volume":"18","author":"Ngo","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104905_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413569","article-title":"Targeting cancer: microenvironment and immunotherapy innovations","volume":"25","author":"Padzi\u0144ska-Pruszy\u0144ska","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104905_bib72","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.104905_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104905_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for treatment of immune adverse events and its impact on tumor response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104905_bib75","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.str.2016.06.026","article-title":"Structure and dynamics of PD-L1 and an Ultra-High-Affinity PD-1 receptor mutant","volume":"24","author":"Pascolutti","year":"2016","journal-title":"Structure"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104905_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072367","article-title":"Modern aspects of immunotherapy with checkpoint inhibitors in melanoma","volume":"21","author":"Petrova","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104905_bib77","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104905_bib78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104905_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104905_bib80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamaoncol.2017.4182","article-title":"Cancer drugs approved based on biomarkers and not tumor Type-FDA approval of pembrolizumab for mismatch Repair-Deficient solid cancers","volume":"4","author":"Prasad","year":"2018","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104905_bib81","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104905_bib83","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/ejoc.201901353","article-title":"Development of glucose transporter (GLUT) inhibitors","volume":"2020","author":"Reckzeh","year":"2020","journal-title":"Eur. J. Org. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib84","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1038\/s41467-023-42883-2","article-title":"Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer","volume":"14","author":"Ren","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104905_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.339066","article-title":"A highly specific aptamer probe targeting PD-L1 in tumor tissue sections: mutation favors specificity","volume":"1185","author":"Ren","year":"2021","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2025.104905_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.12.004","article-title":"Targeting indoleamine-2,3-dioxygenase in cancer: scientific rationale and clinical evidence","volume":"196","author":"Ricciuti","year":"2019","journal-title":"Pharm. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104905_bib87","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104905_bib88","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib89","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104905_bib90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104905_bib91","article-title":"Bioorthogonal chemistry","volume":"1","author":"Scinto","year":"2021","journal-title":"Nat. Rev. Methods Prim."},{"key":"10.1016\/j.critrevonc.2025.104905_bib92","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijbiomac.2019.12.064","article-title":"Enzyme immobilization onto the nanomaterials: application in enzyme stability and prodrug-activated cancer therapy","volume":"143","author":"Sharifi","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2025.104905_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120190","article-title":"Oxaliplatin-\/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer","volume":"255","author":"Shen","year":"2020","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104905_bib94","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1039\/D1SC90047A","article-title":"Correction: mechanochemical activation of disulfide-based multifunctional polymers for theranostic drug release","volume":"12","author":"Shi","year":"2021","journal-title":"Chem. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104905_bib95","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on t lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska","year":"2015","journal-title":"Mol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104905_bib96","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104905_bib97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"Aaps J."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104905_bib98","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ccell.2021.03.001","article-title":"Glucose makes T(reg) lose their temper","volume":"39","author":"Villa","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104905_bib99","article-title":"Inflammation-Regulated nanodrug sensitizes hepatocellular carcinoma to checkpoint blockade therapy by reprogramming the tumor microenvironment","author":"Wang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104905_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz8985","article-title":"Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104905_bib101","article-title":"Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104905_bib102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104905_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120791","article-title":"Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity","volume":"272","author":"Yang","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory t cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104905_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol."},{"issue":"34","key":"10.1016\/j.critrevonc.2025.104905_bib107","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1021\/jacs.3c07687","article-title":"Harnessing the lysosomal sorting signals of the Cation-Independent Mannose-6-Phosphate receptor for targeted degradation of membrane proteins","volume":"145","author":"Yu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"7851","key":"10.1016\/j.critrevonc.2025.104905_bib108","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104905_bib109","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently engineered nanobody chimeras for targeted membrane protein degradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104905_bib110","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-024-49825-6","article-title":"An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104905_bib111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume":"1248","author":"Zhang","year":"2020","journal-title":"Adv. Exp. Med Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104905_bib112","doi-asserted-by":"crossref","first-page":"11951","DOI":"10.1021\/acs.jmedchem.3c00557","article-title":"A Nanobody-Bioorthogonal catalyst conjugate triggers spatially confined prodrug activation for combinational Chemo-immunotherapy","volume":"66","author":"Zhao","year":"2023","journal-title":"J. Med Chem."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:19:43Z","timestamp":1758590383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":112,"alternative-id":["S1040842825002938"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104905","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress and future perspectives of prodrug strategies for immune checkpoint inhibitors in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104905"}}